| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4376 | Rbm2-1b | Novel dual inhibitor of dihydroceramide desaturase (dhCerDS) and acid ceramidase (ACDase) |
|
| DCC4377 | Rbm2-1d | Novel dual inhibitor of dihydroceramide desaturase (dhCerDS) and acid ceramidase (ACDase) |
|
| DCC4378 | Rbpi-3 | Selective inhibitor of poly(ADP-Ribose) glycohydrolase (PARG) |
|
| DCC4379 | Rc-33 Hydrochloride | Novel highly potent, selective, and metabolically stable σ1 receptor agonist potentiating NGF-induced neurite outgrowth |
|
| DCC4380 | Rdrp Inhibitor 11q | Novel Potent Broad-Spectrum Inhibitor of Influenza A Virus RNA-Dependent RNA Polymerase (RdRp) |
|
| DCC4381 | Rds-1997 | Novel HIV-1 Integrase Inhibitor |
|
| DCC4382 | Rds-2197 | Novel HIV-1 Integrase Inhibitor |
|
| DCC4383 | Recql5-in-4a | Novel potent inhibitor of RECQL5-helicase activity, and stabilizing RECQL5-RAD51 physical interaction, leading to impaired HRR and preferential killing of RECQL5-expressing breast cancer |
|
| DCC4384 | Redoxal | Novel Prenyltransferase Inhibitor with In Vitro and In Vivo Antibacterial Activity |
|
| DCC4385 | Redx03863 | Novel potent inhibitor of the supercoiling and ATPase reactions of DNA gyrase, inhibiting gyrase by preventing the binding of ATP |
|
| DCC4386 | Redx04739 | Novel inhibitor of the supercoiling and ATPase reactions of DNA gyrase, inhibiting gyrase by preventing the binding of ATP and showing selectivity against M. smegmatis. |
|
| DCC4387 | regacin | Novel specific inhibitor of the ability of RegA to activate its target promoters, reducing expression of a number of proteins required for virulence |
|
| DCC4388 | Remeglurant | Novel selective antagonist of the mGlu5 receptor |
|
| DCC4389 | Remifentanil | Potent ultra short-acting synthetic unique opioid analgesic |
|
| DCC4390 | Renzapride Hydrochloride | 5-HT3 antagonist and 5-HT4 agonist, also acting as a 5-HT2B antagonist |
|
| DCC4391 | Rep8839 | Novel bacterial methionyl t-RNA synthetase (MRS) inhibitor, hampering Plasmodium growth very effectively |
|
| DCC4392 | Repinotan Hydrochloride | Selective 5-HT1A receptor agonist |
|
| DCC4393 | Resazurin | Oxidation-reduction indicator in cell viability |
|
| DCC4394 | Resiniferatoxin | Potent VR1 vanilloid receptor agonist, activating protein kinase C |
|
| DCC4395 | Resorcinolnaphthalein | Angiotensin-converting enzyme 2 (ACE2) activator, acting as a modulator on RAAS and KKS activation during COVID-19 |
|
| DCC4396 | Resorufin-r1 | Red-absorbing, water-soluble, and iodinated resorufin derivative, being selectively activated with a monoamine oxidase (MAO) enzyme, showing high 1O 2 generation yields in aqueous solutions upon addition of MAO isoforms |
|
| DCC4397 | resveratrol-3-sulfate | Metabolite of Resveratrol |
|
| DCC4398 | Resveratrol-4’-sulfate | Metabolite of Resveratrol |
|
| DCC4399 | Retro-2.1 | Novel potent inhibitor of EBOV infection and entry |
|
| DCC4400 | Rev1/ubm2 Inhibitor | Novel inhibitor of the REV1/UbPCNA interaction, directly binding to REV1 UBM2 and preventing DNA damage tolerance (DDT) |
|
| DCC4401 | Revamilast | Novel phosphodiesterase IV (PDE4) inhibitor for the treatment of Asthma and Rheumatoid Arthritis |
|
| DCC4402 | Reveromycins Inducer Br-1 | Novel biomediator that induces reveromycins production at the wide range of concentrations without affecting cell growth |
|
| DCC4403 | Rf04289 | Novel TLR2 activator |
|
| DCC4404 | Rf3286 | Novel Highly Selective Neuropeptide FF1 Receptor Antagonist, Potently Preventing Opioid-Induced Hyperalgesia |
|
| DCC4405 | Rf470dl | Novel fluorescent D-amino acid for labeling peptidoglycans (PG) in live bacteria |
|
